Show simple item record

dc.contributor.authorBecker, Richard C.
dc.contributor.authorTerrin, Michael L.
dc.contributor.authorRoss, Richard
dc.contributor.authorKnatterud, Genell L.
dc.contributor.authorDesvigne-Nickens, Patrice
dc.contributor.authorGore, Joel M.
dc.contributor.authorBraunwald, Eugene
dc.date2022-08-11T08:09:36.000
dc.date.accessioned2022-08-23T16:37:01Z
dc.date.available2022-08-23T16:37:01Z
dc.date.issued1994-04-15
dc.date.submitted2008-02-29
dc.identifier.citation<p>Ann Intern Med. 1994 Apr 15;120(8):638-45.</p>
dc.identifier.issn0003-4819 (Print)
dc.identifier.doi10.7326/0003-4819-120-8-199404150-00003
dc.identifier.pmid8135447
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38917
dc.description.abstractOBJECTIVES: To assess differences in morbidity and mortality between men and women with acute myocardial infarction treated with thrombolytic therapy and the relation of differences to baseline patient characteristics and clinical features. DESIGN: Secondary analysis of observational findings among women and men enrolled in a clinical trial. SETTING: Hospitals participating in the Thrombolysis in Myocardial Infarction Phase II trial. MEASUREMENTS: Recurrent infarctions and deaths were assessed. MAIN RESULTS: The 6-week mortality rate was greater for women than for men (9% compared with 4%; adjusted relative risk, 1.54; P = 0.01). Death or reinfarction occurred in 15.9% of women and 9.5% of men (adjusted relative risk, 1.33; P = 0.02). Among patients enrolled for treatment with 100 mg of recombinant tissue plasminogen activator and assigned to a conservative strategy of watchful waiting with appropriate backup, the 6-week incidence of death was 7.5% for women and 3.8% for men (P = 0.01). The 6-week incidences of death or reinfarction were 14.2% and 8.9% (P = 0.01) among women and men, respectively. CONCLUSIONS: Among patients in the Thrombolysis in Myocardial Infarction Phase II Trial, who all were diagnosed with myocardial infarction and were eligible to receive thrombolytic therapy, women had higher rates of mortality and morbidity than did men. Older age at the time of myocardial infarction and a history of diabetes accounted for much but probably not all of this difference.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8135447&dopt=Abstract ">Link to article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.7326/0003-4819-120-8-199404150-00003
dc.subjectAge Factors
dc.subjectAged
dc.subjectAngioplasty, Transluminal, Percutaneous Coronary
dc.subjectCombined Modality Therapy
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Infarction
dc.subjectPrognosis
dc.subjectRecombinant Proteins
dc.subjectRecurrence
dc.subjectRisk Factors
dc.subjectSex Factors
dc.subjectTissue Plasminogen Activator
dc.subjectVentricular Function, Left
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleComparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators
dc.typeJournal Article
dc.source.journaltitleAnnals of internal medicine
dc.source.volume120
dc.source.issue8
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/175
dc.identifier.contextkey441940
html.description.abstract<p>OBJECTIVES: To assess differences in morbidity and mortality between men and women with acute myocardial infarction treated with thrombolytic therapy and the relation of differences to baseline patient characteristics and clinical features. DESIGN: Secondary analysis of observational findings among women and men enrolled in a clinical trial. SETTING: Hospitals participating in the Thrombolysis in Myocardial Infarction Phase II trial. MEASUREMENTS: Recurrent infarctions and deaths were assessed. MAIN RESULTS: The 6-week mortality rate was greater for women than for men (9% compared with 4%; adjusted relative risk, 1.54; P = 0.01). Death or reinfarction occurred in 15.9% of women and 9.5% of men (adjusted relative risk, 1.33; P = 0.02). Among patients enrolled for treatment with 100 mg of recombinant tissue plasminogen activator and assigned to a conservative strategy of watchful waiting with appropriate backup, the 6-week incidence of death was 7.5% for women and 3.8% for men (P = 0.01). The 6-week incidences of death or reinfarction were 14.2% and 8.9% (P = 0.01) among women and men, respectively. CONCLUSIONS: Among patients in the Thrombolysis in Myocardial Infarction Phase II Trial, who all were diagnosed with myocardial infarction and were eligible to receive thrombolytic therapy, women had higher rates of mortality and morbidity than did men. Older age at the time of myocardial infarction and a history of diabetes accounted for much but probably not all of this difference.</p>
dc.identifier.submissionpathoapubs/175
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.contributor.departmentThrombosis Research Center
dc.source.pages638-45


This item appears in the following Collection(s)

Show simple item record